​

OmniAb (OABI) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

OmniAb Revenue Highlights

Latest Revenue (Y)

$26.39M

Latest Revenue (Q)

$10.80M

Main Segment (Y)

Service

OmniAb Revenue by Period

OmniAb Revenue by Year

DateRevenueChange
2024-12-31$26.39M-22.75%
2023-12-31$34.16M-42.17%
2022-12-31$59.08M70.02%
2021-12-31$34.75M49.34%
2020-12-31$23.27M27.02%
2019-12-31$18.32M-

OmniAb generated $26.39M in revenue during NA 2024, up -22.75% compared to the previous quarter, and up 144.07% compared to the same period a year ago.

OmniAb Revenue by Quarter

DateRevenueChange
2024-12-31$10.80M158.96%
2024-09-30$4.17M-45.21%
2024-06-30$7.61M100.32%
2024-03-31$3.80M-21.17%
2023-12-31$4.82M-11.96%
2023-09-30$5.48M-21.15%
2023-06-30$6.95M-58.95%
2023-03-31$16.92M-52.13%
2022-12-31$35.34M411.51%
2022-09-30$6.91M-4.01%
2022-06-30$7.20M-25.19%
2022-03-31$9.62M-55.36%
2021-12-31$21.56M243.43%
2021-09-30$6.28M12.39%
2021-06-30$5.58M-15.32%
2021-03-31$6.60M-50.51%
2020-12-31$13.33M167.25%
2020-09-30$4.99M-

OmniAb generated $10.80M in revenue during Q4 2024, up 158.96% compared to the previous quarter, and up 197.26% compared to the same period a year ago.

OmniAb Revenue Breakdown

OmniAb Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23
Royalty$576.00K$1.28M
Service$11.95M$12.18M

OmniAb's latest annual revenue breakdown by segment (product or service), as of Dec 24: Service (95.40%), and Royalty (4.60%).

Quarterly Revenue by Product

Product/ServiceMar 25Dec 24Sep 24Dec 23Sep 23
Royalty$188.00K$258.00K$318.00K$834.00K$451.00K
Service$1.95M$9.47M$2.48M$9.16M$3.02M

OmniAb's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Service (91.19%), and Royalty (8.81%).

OmniAb Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
LEGNLegend Biotech$285.14M$93.99M
GLUEMonte Rosa Therapeutics$75.62M$60.65M
VRNAVerona Pharma$42.28M$76.26M
ITOSiTeos Therapeutics$35.00M-
OABIOmniAb$26.39M$10.80M
IDYAIDEAYA Biosciences$7.00M$7.00M
IPSCCentury Therapeutics$6.59M$109.16M
KROSKeros Therapeutics$3.55M$3.04M
IKNAIkena Oncology--
CGEMCullinan Oncology--
BCABBioAtla--
EWTXEdgewise Therapeutics--
OLMAOlema Pharmaceuticals--
ACETAdicet Bio--
ERASErasca--
PASGPassage Bio--
PMVPPMV Pharmaceuticals--
VORVor Biopharma--

OABI Revenue FAQ

What is OmniAb’s yearly revenue?

OmniAb's yearly revenue for 2024 was $26.39M, representing a decrease of -22.75% compared to 2023. The company's yearly revenue for 2023 was $34.16M, representing a decrease of -42.17% compared to 2022. OABI's yearly revenue for 2022 was $59.08M, representing an increase of 70.02% compared to 2021.

What is OmniAb’s quarterly revenue?

OmniAb's quarterly revenue for Q4 2024 was $10.8M, a 158.96% increase from the previous quarter (Q3 2024), and a 124.06% increase year-over-year (Q4 2023). The company's quarterly revenue for Q3 2024 was $4.17M, a -45.21% decrease from the previous quarter (Q2 2024), and a -23.83% decrease year-over-year (Q3 2023). OABI's quarterly revenue for Q2 2024 was $7.61M, a 100.32% increase from the previous quarter (Q1 2024), and a 9.62% increase year-over-year (Q2 2023).

What is OmniAb’s revenue growth rate?

OmniAb's revenue growth rate for the last 3 years (2022-2024) was -55.33%, and for the last 5 years (2020-2024) was 13.42%.

What are OmniAb’s revenue streams?

OmniAb's revenue streams in c 24 are Royalty, and Service. Royalty generated $576K in revenue, accounting 4.60% of the company's total revenue, down -55.18% year-over-year. Service generated $11.95M in revenue, accounting 95.40% of the company's total revenue, down -1.90% year-over-year.

What is OmniAb’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of OmniAb was Service. This segment made a revenue of $11.95M, representing 95.40% of the company's total revenue.